Profile data is unavailable for this security.
About the company
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
- Revenue in USD (TTM)100.33bn
- Net income in USD31.37bn
- LocationPfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
- Phone+1 (212) 733-2323
- Fax+1 (302) 655-5049
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|PFE:NYQ since |
|Seagen Inc||Announced||13 Mar 2023||13 Mar 2023Announced||2.51%||43.84bn|
|Global Blood Therapeutics Inc||Deal completed||08 Aug 2022||08 Aug 2022Deal completed||-18.04%||5.07bn|
|Biohaven Pharmaceutical Holding Co Ltd||Deal completed||10 May 2022||10 May 2022Deal completed||-16.98%||12.60bn|
|ReViral Ltd||Deal completed||07 Apr 2022||07 Apr 2022Deal completed||-23.62%||525.00m|